156 related articles for article (PubMed ID: 12711183)
1. The influence of carrier and drug morphology on drug delivery from dry powder formulations.
Larhrib H; Martin GP; Marriott C; Prime D
Int J Pharm; 2003 May; 257(1-2):283-96. PubMed ID: 12711183
[TBL] [Abstract][Full Text] [Related]
2. The influence of physical properties and morphology of crystallised lactose on delivery of salbutamol sulphate from dry powder inhalers.
Kaialy W; Martin GP; Larhrib H; Ticehurst MD; Kolosionek E; Nokhodchi A
Colloids Surf B Biointerfaces; 2012 Jan; 89():29-39. PubMed ID: 21962946
[TBL] [Abstract][Full Text] [Related]
3. Engineered mannitol as an alternative carrier to enhance deep lung penetration of salbutamol sulphate from dry powder inhaler.
Kaialy W; Momin MN; Ticehurst MD; Murphy J; Nokhodchi A
Colloids Surf B Biointerfaces; 2010 Sep; 79(2):345-56. PubMed ID: 20537870
[TBL] [Abstract][Full Text] [Related]
4. Characterisation and deposition studies of recrystallised lactose from binary mixtures of ethanol/butanol for improved drug delivery from dry powder inhalers.
Kaialy W; Martin GP; Ticehurst MD; Royall P; Mohammad MA; Murphy J; Nokhodchi A
AAPS J; 2011 Mar; 13(1):30-43. PubMed ID: 21057906
[TBL] [Abstract][Full Text] [Related]
5. The effect of engineered mannitol-lactose mixture on dry powder inhaler performance.
Kaialy W; Larhrib H; Martin GP; Nokhodchi A
Pharm Res; 2012 Aug; 29(8):2139-56. PubMed ID: 22477070
[TBL] [Abstract][Full Text] [Related]
6. The use of different grades of lactose as a carrier for aerosolised salbutamol sulphate.
Larhrib H; Zeng XM; Martin GP; Marriott C; Pritchard J
Int J Pharm; 1999 Nov; 191(1):1-14. PubMed ID: 10556735
[TBL] [Abstract][Full Text] [Related]
7. Humidity-induced changes of the aerodynamic properties of dry powder aerosol formulations containing different carriers.
Zeng XM; MacRitchie HB; Marriott C; Martin GP
Int J Pharm; 2007 Mar; 333(1-2):45-55. PubMed ID: 17064863
[TBL] [Abstract][Full Text] [Related]
8. Characterisation and deposition studies of engineered lactose crystals with potential for use as a carrier for aerosolised salbutamol sulfate from dry powder inhalers.
Larhrib H; Martin GP; Prime D; Marriott C
Eur J Pharm Sci; 2003 Jul; 19(4):211-21. PubMed ID: 12885385
[TBL] [Abstract][Full Text] [Related]
9. Improved aerosolization performance of salbutamol sulfate formulated with lactose crystallized from binary mixtures of ethanol-acetone.
Kaialy W; Ticehurst MD; Murphy J; Nokhodchi A
J Pharm Sci; 2011 Jul; 100(7):2665-84. PubMed ID: 21268026
[TBL] [Abstract][Full Text] [Related]
10. The use of lactose recrystallised from carbopol gels as a carrier for aerosolised salbutamol sulphate.
Ming Zeng X ; Martin GP; Marriott C; Pritchard J
Eur J Pharm Biopharm; 2001 Jan; 51(1):55-62. PubMed ID: 11154904
[TBL] [Abstract][Full Text] [Related]
11. The influence of carrier morphology on drug delivery by dry powder inhalers.
Zeng XM; Martin GP; Marriott C; Pritchard J
Int J Pharm; 2000 Apr; 200(1):93-106. PubMed ID: 10845690
[TBL] [Abstract][Full Text] [Related]
12. Dry powder inhalers: mechanistic evaluation of lactose formulations containing salbutamol sulphate.
Kaialy W; Ticehurst M; Nokhodchi A
Int J Pharm; 2012 Feb; 423(2):184-94. PubMed ID: 22197772
[TBL] [Abstract][Full Text] [Related]
13. The enhanced aerosol performance of salbutamol from dry powders containing engineered mannitol as excipient.
Kaialy W; Martin GP; Ticehurst MD; Momin MN; Nokhodchi A
Int J Pharm; 2010 Jun; 392(1-2):178-88. PubMed ID: 20363301
[TBL] [Abstract][Full Text] [Related]
14. The effects of carrier size and morphology on the dispersion of salbutamol sulphate after aerosolization at different flow rates.
Zeng XM; Martin GP; Marriott C; Pritchard J
J Pharm Pharmacol; 2000 Oct; 52(10):1211-21. PubMed ID: 11092565
[TBL] [Abstract][Full Text] [Related]
15. Liquid crystalline phase as a probe for crystal engineering of lactose: carrier for pulmonary drug delivery.
Patil SS; Mahadik KR; Paradkar AR
Eur J Pharm Sci; 2015 Feb; 68():43-50. PubMed ID: 25460546
[TBL] [Abstract][Full Text] [Related]
16. Novel temperature controlled surface dissolution of excipient particles for carrier based dry powder inhaler formulations.
El-Sabawi D; Price R; Edge S; Young PM
Drug Dev Ind Pharm; 2006 Feb; 32(2):243-51. PubMed ID: 16537205
[TBL] [Abstract][Full Text] [Related]
17. Assessment of Dry Powder Inhaler Carrier Targeted Design: A Comparative Case Study of Diverse Anomeric Compositions and Physical Properties of Lactose.
Pinto JT; Zellnitz S; Guidi T; Roblegg E; Paudel A
Mol Pharm; 2018 Jul; 15(7):2827-2839. PubMed ID: 29856921
[TBL] [Abstract][Full Text] [Related]
18. Physicochemical and in vitro deposition properties of salbutamol sulphate/ipratropium bromide and salbutamol sulphate/excipient spray dried mixtures for use in dry powder inhalers.
Corrigan DO; Corrigan OI; Healy AM
Int J Pharm; 2006 Sep; 322(1-2):22-30. PubMed ID: 16815654
[TBL] [Abstract][Full Text] [Related]
19. Dry powder inhaler performance of spray dried mannitol with tailored surface morphologies as carrier and salbutamol sulphate.
Mönckedieck M; Kamplade J; Fakner P; Urbanetz NA; Walzel P; Steckel H; Scherließ R
Int J Pharm; 2017 May; 524(1-2):351-363. PubMed ID: 28347847
[TBL] [Abstract][Full Text] [Related]
20. Effect of carrier particle shape on dry powder inhaler performance.
Kaialy W; Alhalaweh A; Velaga SP; Nokhodchi A
Int J Pharm; 2011 Dec; 421(1):12-23. PubMed ID: 21945739
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
